🟢 Summit Therapeutics is trading 10.4% up today amid broader biotech strength

Summit Therapeutics is trading at $16.34, up 10.41%, with broader biotech strength supporting a sector-driven explanation for the move.

• No clear Summit-specific announcement on November 3 explains the move; available coverage points to broader biotech strength. The XBI biotech ETF was reported up 2.13% during the regular session.
• The stock has rebounded from its November 2 close of $14.80. Nasdaq reported volume of about 3.35 million shares at 12:54 p.m. ET.